Company intelligence / Profile preview
Harvard Apparatus Regenerative Technology
- Ownership
- Private
- Development stage
- Phase 1
Overview
The company initiated a Phase 1 clinical trial in 10 patients to assess safety and clinical efficacy of their Cellspan Esophageal Implant. The first two sites, Mayo Clinic and University of Michigan, were activated in July and August 2023 to recruit patients. The company previously conducted the world's first successful regeneration of the esophagus in a patient with esophageal cancer in August 2017, performed by Dr. Dennis Wigle at Mayo Clinic, with results published in August 2021[1][6][7].
- Therapeutic areas
- GastroenterologyOncologyRare Diseases
- Modalities
- Stem cell therapyTissue engineering
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Harvard Apparatus Regenerative Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Harvard Apparatus Regenerative Technology.